Description: Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Home Page: www.novonordisk.com
Novo Alle 1
Bagsvaerd,
2880
Denmark
Phone:
45 44 44 88 88
Officers
| Name | Title |
|---|---|
| Mr. Lars Fruergaard Jorgensen | President, CEO & Member of Management Board |
| Mr. Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board |
| Mr. Henrik Ehlers Wulff | Executive VP of Product Supply, Quality & IT and Member of the Management Board |
| Ms. Camilla Sylvest | Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board |
| Dr. Martin Holst Lange | Executive VP of Development & Member of the Management Board |
| Dr. Marcus Schindler Ph.D. | EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board |
| Mr. Maziar Mike Doustdar | Executive VP of International Operations & Member of the Management Board |
| Mr. Douglas J. Langa | Executive VP of North America Operations & Member of Management Board |
| Mr. Ludovic Helfgott | Executive VP, Head of Rare Disease & Member of Management Board |
| Ms. Tania Sabroe | Executive VP of Global People & Organisation and Member of Management Board |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 27.027 |
|---|---|
| Trailing PE: | 38.2143 |
| Price-to-Book MRQ: | 27.7695 |
| Price-to-Sales TTM: | 1.8387 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 71880 |